The field's rapid advances make securing reimbursement an important area of focus, researchers in a recent commentary argued.
The Maryland-based firm reported in a recent proof-of-concept study that It used protease biomarkers to identify patients with lower respiratory tract infections.
Variantyx Combines Long Nanopore, Short Illumina Reads for Rare Disease Whole-Genome Diagnostic Test
Premium
The firm recently launched the Genomic Unity 2.0 assay, which it claims is the first commercial diagnostic rare disease test to include nanopore sequencing.
The company continues to build validation data and believes its lower cost proposition can help it gain leverage in the European market where molecular tests are not reimbursed.
Xgenera has also closed a round of seed financing worth £500,000 and commenced a partnership with YouSeq, a UK technology firm.
The company is targeting its RPPA-based testing to biopharma firms as well as for clinical trial work and to clinicians to help guide therapy in cancer patients.